

November 9, 2024

Q2FY25 Result Update

🗹 Change in Estimates | 🗹 Target | 🔳 Reco

Change in Estimates

	Cur	rent	Pre	vious
	FY26E FY27E		FY26E	FY27E
Rating	RED	UCE	REI	DUCE
Target Price	4	11	5	512
Sales (Rs. m)	77,852	89,001	79,619	92,306
% Chng.	(2.2)	(3.6)		
EBITDA (Rs. m)	12,481	15,130	14,062	17,013
% Chng.	(11.2)	(11.1)		
EPS (Rs.)	12.1	17.2	18.3	24.4
% Chng.	(33.7)	(29.4)		

Key Financials - Consolidated

Y/e Mar	FY24	FY25E	FY26E	FY27E
Sales (Rs. m)	63,720	69,455	77,852	89,001
EBITDA (Rs. m)	9,760	10,036	12,481	15,130
Margin (%)	15.3	14.4	16.0	17.0
PAT (Rs. m)	4,160	3,355	4,397	6,236
EPS (Rs.)	11.5	9.3	12.1	17.2
Gr. (%)	(23.6)	(19.5)	31.1	41.8
DPS (Rs.)	0.6	0.5	0.6	0.9
Yield (%)	0.1	0.1	0.1	0.2
RoE (%)	8.1	6.2	7.6	9.9
RoCE (%)	7.4	6.2	7.2	8.7
EV/Sales (x)	3.2	3.1	2.8	2.5
EV/EBITDA (x)	20.7	21.4	17.4	14.5
PE (x)	41.3	51.3	39.1	27.6
P/BV (x)	3.2	3.1	2.9	2.6

ARTI.BO | ARTO IN

52-W High / Low	Rs.770 / Rs.472
Sensex / Nifty	79,486 / 24,148
Market Cap	Rs.172bn/ \$2,038m
Shares Outstan din g	363m
3M Avg. Daily Value	Rs.1297.87m

Shareholding Pattern (%)

Key Data

Promoter's	42.61
Foreign	9.68
Domestic Institution	18.13
Public & Others	29.58
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	(11.8)	(32.8)	(7.9)
Relative	(9.4)	(37.9)	(24.7)
-			

Swarnendu Bhushan

swarnendubhushan@plindia.com | 91-22-66322260

Saurabh Ahire saurabhahire@plindia.com |

Aarti Industries (ARTO IN)

Rating: REDUCE | CMP: Rs474 | TP: Rs411

Ongoing pressure on margins to continue

Quick Pointers:

- MMA volumes decline to 20.5kt in Q2FY25 from 31.1kt in Q1FY25
- FY28 EBITDA guidance of Rs18-22bn; debt/EBITDA < 2.5x and ROCE > 15%

ARTO reported a topline of Rs16.2bn, marking a sequential decline of 12%, driven by a significant drop in energy business volumes. This segment saw a 36% sequential decline, particularly in MMA, where the gasoline-naphtha delta collapsed. MMA volumes are expected to remain subdued in Q3FY25 as well. In contrast, an uptick in volume was observed across products used in dyes, pigments, and polymer additives, while the agrochemical segment remained soft. Margins are likely to remain under pressure throughout CY25 due to ongoing dumping from China. The management anticipates EBITDA to grow to Rs18-22bn by FY28, though it has revised FY25 EBITDA guidance down to Rs10bn. While we expect some volume-driven growth in products catering to dyes, pigments and polymers, challenges in the agrochemical to persist in near term. As per our understanding, use of MMA for octane boosting is banned in several countries (Link). However, the company maintains that it sells to the very countries where ban is in place. We forecast an EPS CAGR of 14% during FY24-27E. The stock is currently trading at approximately 28x FY27 P/E. We value the stock at 28x FY26E/FY27E EPS and maintain "Reduce" rating with a target price of Rs411.


- Revenue declined by 12% sequentially: Consolidated net revenue stood at Rs16.2bn, +12% YoY/ -12.2% QoQ (PLe: Rs17.4bn, Consensus: Rs16.5bn), Revenue declined sequentially due to volume decrease in energy business products. H1FY25 revenue increased by 21% YoY. Gross margin decreased by 380bps YoY to 37.5% (vs 41.3% in Q2FY24 and 37.7% in Q1FY25).
- EBITDAM declined 450bps YoY: EBITDA decreased 16% YoY and 36% QoQ to Rs1.9bn (PLe: Rs2.7bn, Consensus: Rs2.4bn). EBITDAM stood at 12% (PLe: 15.6%) as against 16.1% in Q2FY24 and 16.5% in Q1FY25, down by 450bps due to higher other expenses. Capitalization of new projects led to higher depreciation. Tax rate remained negative as the company's tax liability is declining and corresponding deferred tax assets are accrued.
- Key concall takeaways: (1) Going forward plans to enter sunrise sectors such as battery chemicals and circular economy. (2) Non-energy business: 22% YoY and 11% QoQ volume growth. (3) Energy business: -1% YoY and -36% QoQ volume growth. (4) Some competitors announced MMA manufacturing, but their capacity is lower as compared to Aarti. (5) ADD on sulfur black announced; Aarti supplies a key intermediate for this product. (6) PAP, an intermediate for paracetamol, witnessed low growth due to pricing pressure (~50% drop in 1 year). (7) Ethylation and NT ramp-up planned over 2 years, no further capex required. (8) Pilot plant commissioned, to fuel new product development. (9) MPP plant to be commissioned by mid-CY25. (10) Longterm contract 2: Plant operating at full capacity. (11) Long term contract 4: Volumes to peak up in FY26.

Q2FY25 Result Overview - Consolidated (Rs mn)

Y/e March	Q2FY25	Q2FY24	YoY gr. (%)	Q2FY25E	% Var.	Q1FY25	QoQ gr. (%)	H1FY25	H1FY24	YoY gr. (%)
Net Sales	16,280	14,540	12.0	17,456	-6.7	18,550	-12.2	34,830	28,680	21.4
Gross Profit	6,110	6,000	1.8	6,572	-7.0	7,000	-12.7	13,110	11,610	12.9
Margin (%)	37.5	41.3		37.6		37.7		37.6	40.5	
EBITDA	1,960	2,340	-16.2	2,732	-28.3	3,060	-35.9	5,020	4,360	15.1
Margin (%)	12.0	16.1		15.6		16.5		14.4	15.2	
Other Income	50	0		25		60		110	0	#DIV/0!
Depreciation	1,080	930	16.1	1,053	2.6	1,020	5.9	2,100	1,820	15.4
EBIT	930	1,410	-34.0	1,704	-45.4	2,100	-55.7	3,030	2,540	19.3
Interest	620	580	6.9	583	6.4	640	-3.1	1,260	980	28.6
PBT before exp	310	830	-62.7	1,121	-72.3	1,460	-78.8	1,770	1,560	13.5
Total Tax	-180	-90		123		80		-100	-70	
ETR (%)	-58.1	-10.8		11.0		5.5		-5.6	-4.5	
Adj. PAT	490	920	-46.7	998	-50.9	1,380	-64.5	1,870	1,630	14.7
Exceptional Items	-20	0		0		0		-20	0	
PAT	510	920	-44.6	998	-48.9	1,380	-63.0	1,890	1,630	16.0


Source: Company, PL

Exhibit 1: Revenue to grow at CAGR of 12% over FY24-27E




Source: Company, PL






Source: Company, PL

Exhibit 2: EBITDA margin to reach 17% in FY27




Source: Company, PL

Exhibit 4: Return ratios to hover at 9-10%




Source: Company, PL

Exhibit 5: Net D/E to be at 0.7



Source: Company, PL

Exhibit 6: Working capital days at 90-100 days



Source: Company, PL

Financials

Income Statement (Rsm)

Y/e Mar	FY24	FY25E	FY26E	FY27E
Net Revenues	63,720	69,455	77,852	89,001
YoY gr. (%)	(3.7)	9.0	12.1	14.3
Cost of Goods Sold	38,800	43,583	48,244	54,291
Gross Profit	24,920	25,871	29,608	34,710
Margin (%)	39.1	37.2	38.0	39.0
Employee Cost	4,040	4,376	4,671	5,340
Other Expenses	11,120	11,460	12,456	14,240
EBITDA	9,760	10,036	12,481	15,130
YoY gr. (%)	(10.4)	2.8	24.4	21.2
Margin (%)	15.3	14.4	16.0	17.0
Depreciation and Amortization	3,780	4,212	4,975	5,475
EBIT	5,980	5,824	7,506	9,655
Margin (%)	9.4	8.4	9.6	10.8
Net Interest	2,110	2,327	2,770	2,876
Other Income	80	150	150	150
Profit Before Tax	3,950	3,646	4,886	6,929
Margin (%)	6.2	5.2	6.3	7.8
Total Tax	(210)	292	489	693
Effective tax rate (%)	(5.3)	8.0	10.0	10.0
Profit after tax	4,160	3,355	4,397	6,236
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	4,160	3,355	4,397	6,236
YoY gr. (%)	(23.7)	(19.4)	31.1	41.8
Margin (%)	6.5	4.8	5.6	7.0
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	4,160	3,355	4,397	6,236
YoY gr. (%)	(23.7)	(19.4)	31.1	41.8
Margin (%)	6.5	4.8	5.6	7.0
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	4,160	3,355	4,397	6,236
Equity Shares O/s (m)	362	363	363	363
EPS (Rs)	11.5	9.3	12.1	17.2

Balance Sheet Abstract (Rs m)	

Y/e Mar	FY24	FY25E	FY26E	FY27E
Non-Current Assets				
Gross Block	73,984	94,504	1,04,504	1,14,504
Tangibles	73,965	94,485	1,04,485	1,14,485
Intangibles	19	19	19	19
Acc: Dep / Amortization	18,024	22,237	27,212	32,687
Tangibles	17,944	22,157	27,132	32,607
Intangibles	80	80	80	80
Net fixed assets	56,490	72,798	77,823	82,347
Tangibles	56,551	72,858	77,883	82,408
Intangibles	(61)	(61)	(61)	(61)
Capital Work In Progress	12,290	6,770	6,770	6,770
Goodwill	-	-	-	-
Non-Current Investments	1,240	1,175	1,175	1,175
Net Deferred tax assets	1,440	1,440	1,440	1,440
Other Non-Current Assets	-	-	-	-
Current Assets				
Investments	-	-	-	-
Inventories	11,600	11,417	12,798	14,630
Trade receivables	8,260	11,417	12,798	14,630
Cash & Bank Balance	1,300	3,323	1,088	2,172
Other Current Assets	2,680	2,921	3,274	3,743
Total Assets	96,150	1,12,188	1,18,204	1,28,096
Equity				
Equity Share Capital	1,810	1,813	1,813	1,813
Other Equity	51,090	54,277	58,454	64,378
Total Networth	52,900	56,089	60,267	66,191
Non-Current Liabilities				
Long Term borrowings	15,240	21,000	21,000	20,000
Provisions	-	-	-	-
Other non current liabilities	2,240	2,240	2,240	2,240
Current Liabilities				
ST Debt / Current of LT Debt	16,600	24,737	25,595	29,261
Trade payables	5,210	3,806	4,266	4,877
Other current liabilities	3,950	4,305	4,826	5,517
Total Equity & Liabilities	96,150	1,12,188	1,18,204	1,28,096

Source: Company Data, PL Research

Source: Company Data, PL Research

Cash Flow (Rs m)

Y/e Mar	FY24	FY25E	FY26E	FY27E
PBT	3,950	3,646	4,886	6,929
Add. Depreciation	3,780	4,212	4,975	5,475
Add. Interest	2,110	2,327	2,770	2,876
Less Financial Other Income	80	150	150	150
Add. Other	30	(150)	(150)	(150)
Op. profit before WC changes	9,880	10,036	12,481	15,130
Net Changes-WC	3,063	(4,377)	(2,298)	(3,051)
Direct tax	(910)	(256)	(436)	(623)
Net cash from Op. activities	12,033	5,403	9,747	11,456
Capital expenditures	(13,040)	(15,000)	(10,000)	(10,000)
Interest / Dividend Income	-	150	150	150
Others	(60)	65	-	-
Net Cash from Invt. activities	(13,100)	(14,785)	(9,850)	(9,850)
Issue of share cap. / premium	-	3	-	-
Debt changes	3,100	13,897	858	2,666
Dividend paid	(540)	(168)	(220)	(312)
Interest paid	(2,110)	(2,327)	(2,770)	(2,876)
Others	(90)	-	-	-
Net cash from Fin. activities	360	11,405	(2,132)	(522)
Net change in cash	(707)	2,023	(2,235)	1,084
Free Cash Flow	(1,247)	(9,597)	(253)	1,456

Y/e Mar	FY24	FY25E	FY26E	FY27E
Per Share(Rs)				
EPS	11.5	9.3	12.1	17.2
CEPS	21.9	20.9	25.9	32.3
BVPS	146.1	154.7	166.3	182.6
FCF	(3.4)	(26.5)	(0.7)	4.0
DPS	0.6	0.5	0.6	0.9
Return Ratio(%)				
RoCE	7.4	6.2	7.2	8.7
ROIC	7.9	5.9	6.6	7.9
RoE	8.1	6.2	7.6	9.9
Balance Sheet				
Net Debt : Equity (x)	0.6	0.8	0.8	0.7
Net Working Capital (Days)	84	100	100	100
Valuation(x)				
PER	41.3	51.3	39.1	27.6
P/B	3.2	3.1	2.9	2.6
P/CEPS	21.6	22.7	18.3	14.7
EV/EBITDA	20.7	21.4	17.4	14.5
EV/Sales	3.2	3.1	2.8	2.5
Dividend Yield (%)	0.1	0.1	0.1	0.2

Source: Company Data, PL Research

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q3FY24	Q4FY24	Q1FY25	Q2FY25
Net Revenue	17,320	17,730	18,550	16,280
YoY gr. (%)	3.9	7.1	31.2	12.0
Raw Material Expenses	11,010	10,710	11,550	10,170
Gross Profit	6,310	7,020	7,000	6,110
Margin (%)	36.4	39.6	37.7	37.5
EBITDA	2,600	2,830	3,060	1,960
YoY gr. (%)	(9.9)	12.7	51.5	(16.2)
Margin (%)	15.0	16.0	16.5	12.0
Depreciation / Depletion	970	980	1,020	1,080
EBIT	1,630	1,850	2,040	880
Margin (%)	9.4	10.4	11.0	5.4
Net Interest	540	590	640	620
Other Income	80	-	60	50
Profit before Tax	1,170	1,260	1,460	330
Margin (%)	6.8	7.1	7.9	2.0
Total Tax	(70)	(60)	80	(180)
Effective tax rate (%)	(6.0)	(4.8)	5.5	(54.5)
Profit after Tax	1,240	1,320	1,380	510
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	1,240	1,320	1,380	510
YoY gr. (%)	(9.2)	(10.8)	94.4	(44.6)
Margin (%)	7.2	7.4	7.4	3.1
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	1,240	1,320	1,380	510
YoY gr. (%)	(9.2)	(10.8)	94.4	(44.6)
Margin (%)	7.2	7.4	7.4	3.1
Other Comprehensive Income	(70)	(70)	10	(30)
Total Comprehensive Income	1,170	1,250	1,390	480
Avg. Shares O/s (m)	363	363	363	363
EPS (Rs)	3.4	3.6	3.8	1.4

Source: Company Data, PL Research



Aarti Industries

Price Chart



).	Date	Rating	TP (Rs.)	Share Price (Rs.)	
	05-Oct-24	Reduce	512	551	
	13-Aug-24	Reduce	635	735	
	04-Jul-24	Reduce	634	718	
	13-May-24	Reduce	595	669	
	09-Apr-24	Reduce	599	705	
	11-Feb-24	Reduce	599	663	
	08-Jan-24	Reduce	584	629	

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Aarti Industries	Reduce	512	551
2	Ashok Leyland	Accumulate	257	222
3	Bajaj Auto	Hold	11,859	11,617
4	Bharat Forge	Accumulate	1,369	1,437
5	Bharat Petroleum Corporation	Hold	316	310
6	Bharti Airtel	Accumulate	1,782	1,637
7	CEAT	Hold	3,063	2,973
8	Clean Science and Technology	Hold	1,526	1,484
9	DeepakNitrite	Reduce	2,582	3,000
10	Divgi Torqtransfer Systems	Hold	633	591
11	Eicher Motors	BUY	5,416	4,668
12	Endurance Technologies	BUY	2,835	2,437
13	Exide Industries	Hold	520	481
14	Fine Organic Industries	Accumulate	5,568	5,142
15	GAIL (India)	Hold	204	209
16	Gujarat Fluorochemicals	Reduce	3,770	4,158
17	Gujarat Gas	Hold	565	541
18	Gujarat State Petronet	Hold	380	390
19	Hero Motocorp	Accumulate	5,906	5,495
20	Hindustan Petroleum Corporation	Accumulate	412	372
21	Indian Oil Corporation	Hold	156	147
22	Indraprastha Gas	Hold	402	417
23	Jubilant Ingrevia	Hold	695	682
24	Laxmi Organic Industries	Reduce	240	270
25	Mahanagar Gas	Accumulate	1,627	1,497
26	Mahindra & Mahindra	BUY	3,458	3,060
27	Mangalore Refinery & Petrochemicals	Sell	128	173
28	Maruti Suzuki	BUY	14,586	11,046
29	Navin Fluorine International	Accumulate	3,523	3,307

PL's Recommendation Nomenclature (Absolute Performance)

Buy	:	> 15%
Accumulate	:	5% to 15%
Hold	:	+5% to -5%
Reduce	:	-5% to -15%
Sell	:	< -15%
Not Rated (NR)	:	No specific call on the stock
Under Review (UR)	:	${\sf Ratinglikelytochangeshortly}$



ANALYST CERTIFICATION

(Indian Clients)

We/I, Mr. Swarnendu Bhushan- IIT, MBA Finance, Mr. Saurabh Ahire- MBA, Passed CFA Level II Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever na ture for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Swarnendu Bhushan- IIT, MBA Finance, Mr. Saurabh Ahire-MBA, Passed CFA Level II Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our dients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or actas an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/ α transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com